Kiniksa Q1 2022 ARCALYST net revenue $22.2M; net loss narrows to $25.2M; FY2022 guidance $115-130M

Kiniksa Pharmaceuticals International, plc

2022-Q1 EPS reported -$0.36 revenue$32,189,000

ARCALYST net revenue $22.2M in Q1 2022 versus $0 in Q1 2021; total revenue $32.2M including $10M collaboration revenue.
Net loss $25.2M, improved from $49.5M loss in Q1 2021; cash $145.6M, no debt.
Full-year 2022 ARCALYST net revenue guidance $115M-$130M; cash expected to fund operations into at least 2024.
Strategic collaboration with Huadong Medicine for Asia Pacific rights: $22M upfront, up to $640M milestones, tiered royalties.
Over 400 prescribers for ARCALYST since launch; ~95% coverage approval; ~60% patients retained on therapy through Q1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.